JP Morgan Chase
DOVA

JP Morgan Chase’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

JP Morgan Chase’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,731
Closed -$76K – 6082
2019
Q3 		$76K Buy
2,731
+488
+22% +$7.91K ﹤0.01% 4998
2019
Q2 		$30K Sell
2,243
-631
-22% -$6K ﹤0.01% 5361
2019
Q1 		$26K Sell
2,874
-135
-4% -$1.1K ﹤0.01% 5347
2018
Q4 		$23K Buy
3,009
+281
+10% +$4.52K ﹤0.01% 5300
2018
Q3 		$57K Buy
2,728
+337
+14% +$8.03K ﹤0.01% 5156
2018
Q2 		$72K Sell
2,391
-2,954
-55% -$80.4K ﹤0.01% 4955
2018
Q1 		$145K Buy
5,345
+3,195
+149% +$95.6K ﹤0.01% 4475
2017
Q4 		$62K Buy
+2,150
New +$58.9K ﹤0.01% 4829
2017
Q3 		– Sell
-17,135
Closed -$382K – 5316
2017
Q2 		$382K Buy
+17,135
New +$361K ﹤0.01% 3819

JP Morgan Chase's DOVA Position: Q4 2019 in Review

JP Morgan Chase sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 2,731 shares — an estimated $76K sold.

JP Morgan Chase first reported a position in DOVA in Q2 2017 and held it in 9 quarters. The position peaked at $382K in Q2 2017. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

  • JP Morgan Chase reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • JP Morgan Chase sold 2,731 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $76K.
  • JP Morgan Chase first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 9 quarters.
  • JP Morgan Chase's Dova Pharmaceuticals, Inc. Common Stock position peaked at $382K in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on JP Morgan Chase's 13F filing for Q4 2019, filed 11 Feb 2020.